GO:0060588 negative regulation of lipoprotein lipid oxidation: Protective Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060588 describes any process that decreases the rate, frequency, or extent of lipoprotein lipid oxidation, a key protective mechanism against atherosclerosis.
• Lipoprotein lipid oxidation, especially oxidized LDL (oxLDL) formation, is a central driver of endothelial dysfunction, foam cell formation, and plaque instability.
• Key genes and proteins that negatively regulate lipoprotein lipid oxidation include PIM1, TFEB, eNOS, CD36, and miR221-5p, which modulate oxidative stress, autophagy, and lipid uptake.
• Dysregulation of this process is linked to atherosclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD), and abdominal aortic aneurysm.
• Experimental models for studying GO:0060588 include CRISPR knockout of PIM1 or TFEB, point mutations in eNOS, and overexpression of miR221-5p in endothelial or macrophage cells.
• Therapeutic strategies such as berberine and hydrogen sulfide donors enhance negative regulation of lipoprotein lipid oxidation, offering protection against vascular injury.
Description
Lipoprotein lipid oxidation is a biochemical process in which lipoproteins, such as low-density lipoprotein (LDL), undergo oxidative modification of their lipid components, generating oxidized LDL (oxLDL). This modification is a hallmark of early atherogenesis and contributes to endothelial activation, macrophage foam cell formation, and plaque instability. The Gene Ontology term GO:0060588, negative regulation of lipoprotein lipid oxidation, encompasses any cellular or molecular process that decreases the rate, frequency, or extent of this oxidative modification. Understanding this regulatory process is critical because it represents a protective barrier against cardiovascular and metabolic diseases. Researchers study GO:0060588 to identify therapeutic targets that can boost endogenous antioxidant and anti-inflammatory pathways, thereby preventing or slowing disease progression.
negative regulation of lipoprotein lipid oxidation At A Glance
| GO ID | GO:0060588 |
|---|---|
| GO term | negative regulation of lipoprotein lipid oxidation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of lipoprotein lipid oxidation, protecting against oxidative modification of lipoproteins |
| Related process | Regulation of oxidative stress, autophagy, and lipid metabolism |
| Key regulators | PIM1, TFEB, eNOS, CD36, miR221-5p |
| Disease relevance | Atherosclerosis, MASLD, abdominal aortic aneurysm |
What Is GO:0060588?
GO:0060588 is a biological process defined as any process that decreases the rate, frequency, or extent of lipoprotein lipid oxidation. Lipoprotein lipid oxidation itself is the modification of a lipoprotein by oxidation of the lipid group. In other words, this term captures all molecular and cellular events that inhibit or reduce the oxidative damage to lipids carried by lipoproteins, such as LDL, HDL, and VLDL.
Why Is negative regulation of lipoprotein lipid oxidation Important in Cell Biology?
GO:0060588 is critically important because lipoprotein lipid oxidation is a primary trigger of atherosclerosis and related cardiovascular diseases. Oxidized LDL promotes endothelial-to-mesenchymal transition, a process that aggravates plaque formation and instability. Negative regulation of this oxidation helps maintain vascular homeostasis, reduces foam cell formation, and preserves plaque stability. Moreover, this process intersects with autophagy, ferroptosis, and immune regulation, making it a central node in metabolic and inflammatory diseases. Understanding how cells negatively regulate lipoprotein lipid oxidation can reveal new therapeutic targets for preventing or treating atherosclerosis, MASLD, and aortic aneurysm.
• Protects against atherosclerosis by reducing oxidized LDL formation and endothelial activation.
• Preserves atherosclerotic plaque stability through TFEB-mediated autophagy.
• Limits ferroptosis of regulatory T cells in metabolic dysfunction-associated steatotic liver disease.
• Modulates macrophage polarization and extracellular vesicle signaling in abdominal aortic aneurysm.
• Enhances endothelial nitric oxide synthase (eNOS) function and nitric oxide bioavailability.
• Provides a mechanistic basis for natural compounds like berberine in intestinal and vascular protection.
• Influences lipid metabolism and exercise-induced adaptations.
• Serves as a biomarker and therapeutic target for cardiovascular risk assessment.
• Connects oxidative stress, autophagy, and inflammation in metabolic diseases.
• Offers opportunities for CRISPR-based gene editing to validate causal genes.
What Happens During negative regulation of lipoprotein lipid oxidation?
Inhibition of oxidative modification of lipoprotein lipids
In simple terms: Cells deploy antioxidant systems to stop LDL particles from becoming oxidized.
The primary event in GO:0060588 is the suppression of oxidative reactions that modify the lipid moiety of lipoproteins. This can occur through enzymatic antioxidant defenses, such as upregulation of eNOS, which reduces reactive oxygen species (ROS) and prevents LDL oxidation. Additionally, proteins like PIM1 can influence endothelial-to-mesenchymal transition and oxidative stress, thereby indirectly limiting lipoprotein lipid oxidation. The net effect is a decrease in the generation of oxidized LDL (oxLDL), a key initiator of atherosclerosis.
Enhancement of autophagy and lysosomal degradation
In simple terms: Autophagy helps cells clear damaged components and reduces oxidative stress that would otherwise oxidize lipoproteins.
TFEB (transcription factor EB) is a master regulator of autophagy and lysosomal biogenesis. Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB-mediated autophagy, which in turn negatively regulates lipoprotein lipid oxidation by removing damaged mitochondria and reducing ROS. This autophagic clearance lowers the oxidative burden on lipoproteins, contributing to plaque stability.
Modulation of lipid uptake and foam cell formation
In simple terms: Reducing the uptake of oxidized LDL prevents macrophages from becoming foam cells.
CD36 is a scavenger receptor that mediates the uptake of oxidized LDL. In metabolic dysfunction-associated steatotic liver disease, CD36-mediated uptake of oxLDL induces ferroptosis in double-negative regulatory T cells. Negative regulation of lipoprotein lipid oxidation can be achieved by limiting CD36 expression or activity, thereby reducing oxLDL internalization and downstream oxidative stress. Similarly, miR221-5p in M2 macrophage-derived extracellular vesicles modulates macrophage polarization and protects against abdominal aortic aneurysm, partly by reducing oxidative lipid uptake.
Regulation of endothelial and smooth muscle cell phenotype
In simple terms: Keeping endothelial and smooth muscle cells in a healthy state prevents them from promoting lipoprotein oxidation.
Endothelial-to-mesenchymal transition (EndMT) is a process that aggravates atherosclerosis and is instigated by PIM1. Negative regulation of lipoprotein lipid oxidation involves maintaining endothelial cell homeostasis and preventing EndMT, which otherwise increases oxidative stress and lipoprotein modification. Integrin-specific signaling drives ER stress-dependent atherogenic endothelial activation, and blocking this pathway can enhance negative regulation of lipoprotein lipid oxidation. In smooth muscle cells, hydrogen sulfide promotes plaque stability via TFEB-mediated autophagy, further illustrating cell-type-specific regulation.
Systemic metabolic and exercise-induced adaptations
In simple terms: Exercise and metabolic factors can boost the body's ability to prevent lipoprotein oxidation.
Exercise regulates lipid metabolism and can enhance antioxidant capacity, thereby negatively regulating lipoprotein lipid oxidation. Metabolic pathways that improve insulin sensitivity and reduce inflammation also contribute to this process. Understanding these systemic adaptations provides a framework for lifestyle and pharmacological interventions that support GO:0060588.
Key Genes Involved in GO:0060588 negative regulation of lipoprotein lipid oxidation
The following genes and proteins have been experimentally linked to the negative regulation of lipoprotein lipid oxidation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PIM1 | Instigates endothelial-to-mesenchymal transition; its inhibition reduces oxidative stress and atherosclerosis | CRISPR knockout to study EndMT and plaque formation |
| TFEB | Promotes autophagy and lysosomal biogenesis; mediates plaque stability | Knockout or overexpression to assess autophagy in atherosclerosis |
| eNOS | Produces nitric oxide; reduces ROS and prevents LDL oxidation | Point mutations to modulate NO production |
| CD36 | Scavenger receptor for oxidized LDL; mediates ferroptosis in T cells | Knockout to block oxLDL uptake in MASLD models |
| miR221-5p | Modulates macrophage polarization; protects against abdominal aortic aneurysm | Overexpression in macrophages to study EV-mediated protection |
| H2S-producing enzymes (CBS, CSE) | Generate hydrogen sulfide that promotes TFEB-mediated autophagy | Knockout to reduce H2S and impair plaque stability |
| Integrins | Drive ER stress-dependent endothelial activation | Knockdown to prevent atherogenic signaling |
| Berberine targets (e.g., AMPK) | Mediate protective effects against LPS-induced injury | Pharmacological activation in intestinal models |
| Lipid metabolism enzymes (e.g., lipases) | Regulate lipid turnover and oxidative susceptibility | Overexpression or knockout in exercise studies |
| Antioxidant enzymes (e.g., SOD, catalase) | Directly neutralize ROS that oxidize lipoproteins | Knock-in of tagged versions for imaging |
| Autophagy-related genes (ATG5, ATG7) | Facilitate autophagic clearance of oxidized lipids | Conditional knockout in vascular cells |
| Transcription factors (e.g., Nrf2) | Upregulate antioxidant response elements | CRISPR activation to boost antioxidant defenses |
| Inflammatory cytokines (TNF-alpha, IL-6) | Modulate oxidative stress and lipoprotein modification | Knockout to reduce inflammation-driven oxidation |
| Ferroptosis regulators (GPX4, ACSL4) | Control lipid peroxidation and ferroptosis | Overexpression or knockout in T cells |
| Extracellular vesicle cargo (miRNAs) | Mediate intercellular communication to reduce oxidation | Engineered EVs for delivery |
| Caveolae proteins (caveolin-1) | Regulate eNOS signaling in caveolae | Knockout to study eNOS localization |
How Is negative regulation of lipoprotein lipid oxidation Regulated?
The negative regulation of lipoprotein lipid oxidation is controlled by multiple intersecting pathways. Autophagy, particularly TFEB-mediated, plays a central role by clearing damaged mitochondria and reducing ROS. The eNOS/nitric oxide pathway in caveolae directly inhibits oxidative modification of LDL. Inflammatory signaling, such as integrin-specific ER stress, can suppress this negative regulation, leading to endothelial activation. Metabolic hormones and exercise also modulate lipid metabolism and antioxidant capacity, thereby influencing GO:0060588. Additionally, microRNAs such as miR221-5p in extracellular vesicles can reprogram macrophage polarization to enhance protective effects. These regulatory layers provide multiple entry points for therapeutic intervention.
negative regulation of lipoprotein lipid oxidation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PIM1 | Atherosclerosis, endothelial-to-mesenchymal transition | CRISPR knockout in endothelial cells |
| TFEB | Atherosclerotic plaque stability, autophagy | Knockout or overexpression in smooth muscle cells |
| CD36 | MASLD, ferroptosis of regulatory T cells | Knockout in hepatocytes or T cells |
| miR221-5p | Abdominal aortic aneurysm, macrophage polarization | Overexpression in macrophages or EVs |
| eNOS | Endothelial dysfunction, LDL oxidation | Point mutation knock-in in endothelial cells |
Atherosclerosis and cardiovascular disease
Atherosclerosis is the primary disease linked to impaired negative regulation of lipoprotein lipid oxidation. PIM1 instigates endothelial-to-mesenchymal transition, aggravating atherosclerosis, and its inhibition restores protective mechanisms. Hydrogen sulfide promotes atherosclerotic plaque stability via TFEB-mediated autophagy, directly enhancing negative regulation of lipoprotein lipid oxidation. Integrin-specific signaling drives ER stress-dependent atherogenic endothelial activation, which can be targeted to prevent plaque formation. eNOS regulation in caveolae is critical for maintaining nitric oxide bioavailability and preventing LDL oxidation.
Metabolic dysfunction-associated steatotic liver disease (MASLD)
In MASLD, CD36-mediated uptake of oxidized LDL induces ferroptosis in double-negative regulatory T cells, exacerbating liver injury. Negative regulation of lipoprotein lipid oxidation would limit oxLDL uptake and prevent ferroptosis, thereby protecting against MASLD progression. This highlights the importance of GO:0060588 in metabolic liver diseases.
Abdominal aortic aneurysm (AAA)
M2 macrophage-derived extracellular vesicles protect against abdominal aortic aneurysm by modulating macrophage polarization through miR221-5p. This protection involves reducing oxidative stress and lipoprotein lipid oxidation, suggesting that enhancing GO:0060588 could be therapeutic in AAA.
Intestinal injury and inflammation
Berberine exerts protective effects against LPS-induced intestinal injury, partly through antioxidant and anti-inflammatory mechanisms that may involve negative regulation of lipoprotein lipid oxidation. This suggests a broader role for GO:0060588 in inflammatory conditions beyond cardiovascular disease.
From negative regulation of lipoprotein lipid oxidation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PIM1 knockout reduce endothelial-to-mesenchymal transition and atherosclerosis? | CRISPR knockout of PIM1 in mouse endothelial cells or ApoE-/- mice |
| Can TFEB overexpression enhance plaque stability via autophagy? | Knock-in of constitutively active TFEB in vascular smooth muscle cells |
| Does CD36 knockout prevent oxLDL-induced ferroptosis in MASLD? | CRISPR knockout of CD36 in primary hepatocytes or T cells |
| Can miR221-5p overexpression in macrophages protect against AAA? | Lentiviral overexpression of miR221-5p in macrophages |
| Does eNOS point mutation affect nitric oxide production and LDL oxidation? | CRISPR point mutation (e.g., S1177D) in endothelial cells |
| Can berberine activate AMPK to negatively regulate lipoprotein lipid oxidation? | Pharmacological treatment in intestinal epithelial cells with AMPK knockout |
How to Study the negative regulation of lipoprotein lipid oxidation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene function loss | Identify negative regulators of lipoprotein lipid oxidation |
| Oxidized LDL ELISA | Concentration of oxLDL | Quantify lipid oxidation in cell culture or plasma |
| MDA/4-HNE assay | Lipid peroxidation products | Assess oxidative stress in cells or tissues |
| Western blot for LC3B/p62 | Autophagic flux | Determine autophagy involvement |
| Ferroptosis markers (GPX4, ACSL4) | Ferroptotic cell death | Link to CD36-mediated oxLDL uptake |
| miRNA profiling | Expression of regulatory miRNAs | Identify EV-mediated protection |
| Immunofluorescence for eNOS | Subcellular localization | Study caveolae regulation |
| RNA-seq | Transcriptomic changes | Global view of pathways regulated by GO:0060588 |
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate lipoprotein lipid oxidation. For example, knocking out PIM1 or TFEB in endothelial cells followed by oxLDL treatment and measurement of lipid peroxidation can reveal causal roles. Libraries targeting autophagy or antioxidant pathways are particularly useful.
Lipid peroxidation and oxidative stress assays
Measuring malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), or oxidized LDL levels using ELISA or mass spectrometry quantifies the extent of lipoprotein lipid oxidation. These assays are used to assess the impact of gene knockouts or overexpression on GO:0060588.
Autophagy and ferroptosis monitoring
LC3B puncta formation, p62 degradation, and ferroptosis markers (e.g., GPX4, ACSL4) can be assessed by Western blot or immunofluorescence to determine whether negative regulation of lipoprotein lipid oxidation involves autophagy or ferroptosis.
Extracellular vesicle and miRNA analysis
Isolating extracellular vesicles from conditioned media and profiling miRNAs (e.g., miR221-5p) can reveal intercellular mechanisms that modulate lipoprotein lipid oxidation. Functional studies with miRNA mimics or inhibitors validate their role.
How CRISPR Can Be Used to Study GO:0060588 negative regulation of lipoprotein lipid oxidation
Knockout
CRISPR knockout of genes such as PIM1, TFEB, or CD36 can abolish their protective effects, leading to increased lipoprotein lipid oxidation and disease phenotypes. For example, PIM1 knockout reduces endothelial-to-mesenchymal transition and atherosclerosis in mouse models. TFEB knockout impairs autophagy and reduces plaque stability. CD36 knockout prevents oxLDL uptake and ferroptosis in MASLD.
Point Mutation
Point mutations can be introduced to modulate protein activity. For instance, mutating eNOS at phosphorylation sites (e.g., S1177D) can enhance nitric oxide production and negatively regulate lipoprotein lipid oxidation. Such models help dissect precise molecular mechanisms without complete gene loss.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-TFEB) allows real-time imaging of autophagy and localization. Knock-in of constitutively active TFEB can enhance autophagy and plaque stability, providing a gain-of-function model for GO:0060588. Similarly, knock-in of mutant eNOS can test specific phosphorylation effects.
Overexpression
Overexpression of protective genes or miRNAs, such as miR221-5p in macrophages, can enhance negative regulation of lipoprotein lipid oxidation and protect against abdominal aortic aneurysm. Overexpression of antioxidant enzymes or berberine targets can also boost this process.
How EDITGENE Supports negative regulation of lipoprotein lipid oxidation Research
Researchers studying negative regulation of lipoprotein lipid oxidation-related genes often need to determine whether a candidate gene is causally involved in preventing oxidative modification of lipoproteins. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipoprotein lipid oxidation research.
Frequently Asked Questions About negative regulation of lipoprotein lipid oxidation
What is GO:0060588?
GO:0060588 is the Gene Ontology term for negative regulation of lipoprotein lipid oxidation, a biological process that decreases the rate, frequency, or extent of oxidative modification of lipoproteins.
What genes are involved in negative regulation of lipoprotein lipid oxidation?
Key genes include PIM1, TFEB, eNOS, CD36, and miR221-5p, among others.
How does negative regulation of lipoprotein lipid oxidation protect against atherosclerosis?
It reduces oxidized LDL formation, prevents endothelial-to-mesenchymal transition, enhances autophagy, and stabilizes atherosclerotic plaques.
What diseases are associated with impaired negative regulation of lipoprotein lipid oxidation?
Atherosclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD), and abdominal aortic aneurysm are linked to defects in this process.
What experimental models are used to study GO:0060588?
CRISPR knockout of PIM1 or TFEB, point mutations in eNOS, and overexpression of miR221-5p in endothelial or macrophage cells are common models.
How can CRISPR screening identify regulators of lipoprotein lipid oxidation?
Genome-wide knockout or activation screens followed by oxLDL treatment and lipid peroxidation assays can uncover novel genes that negatively regulate this process.
What is the role of TFEB in negative regulation of lipoprotein lipid oxidation?
TFEB promotes autophagy and lysosomal biogenesis, which clears damaged mitochondria and reduces ROS, thereby limiting lipoprotein lipid oxidation and enhancing plaque stability.
How does CD36 contribute to lipoprotein lipid oxidation?
CD36 mediates the uptake of oxidized LDL, which can induce ferroptosis in regulatory T cells; negative regulation of lipoprotein lipid oxidation involves limiting CD36 activity.
Can exercise influence negative regulation of lipoprotein lipid oxidation?
Yes, exercise regulates lipid metabolism and enhances antioxidant capacity, contributing to the negative regulation of lipoprotein lipid oxidation.
What EDITGENE services are available for studying GO:0060588?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study genes involved in this process.
Conclusion
GO:0060588, negative regulation of lipoprotein lipid oxidation, is a critical protective process that guards against atherosclerosis, MASLD, and aortic aneurysm by limiting oxidative modification of lipoproteins. Key regulators such as PIM1, TFEB, eNOS, CD36, and miR221-5p offer promising therapeutic targets. Advances in CRISPR gene editing and functional genomics are accelerating the discovery of new players in this pathway. EDITGENE provides end-to-end solutions to validate these targets and translate findings into clinical applications.
References
- 1. Xue Z et al.. 2025. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.. Theranostics 15(2):745-765 PMID: 39744686
- 2. Izadparast F et al.. 2022. Protective effect of berberine against LPS-induced injury in the intestine: a review.. Cell Cycle 21(22):2365-2378 PMID: 35852392
- 3. Chen Z et al.. 2022. Vascular smooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaque stability via TFEB (transcription factor EB)-mediated autophagy.. Autophagy 18(10):2270-2287 PMID: 35090378
- 4. Noland RC. 2015. Exercise and Regulation of Lipid Metabolism.. Prog Mol Biol Transl Sci 135:39-74 PMID: 26477910
- 5. Wei Y et al.. 2025. CD36-mediated uptake of oxidized LDL induces double-negative regulatory T cell ferroptosis in metabolic dysfunction-associated steatotic liver disease.. Metabolism 164:156127 PMID: 39743040
- 6. Ben Dhaou C et al.. 2025. Integrin-specific signaling drives ER stress-dependent atherogenic endothelial activation.. Redox Biol 88:103911 PMID: 41274038
- 7. Mineo C et al.. 2012. Regulation of eNOS in caveolae.. Adv Exp Med Biol 729:51-62 PMID: 22411313
- 8. Ma Y et al.. 2025. M2 macrophage-derived extracellular vesicles protect against abdominal aortic aneurysm by modulating macrophage polarization through miR221-5p.. Cell Mol Biol Lett 30(1):96 PMID: 40784924
